| August 9, 2012 | ISSUE NUMBER 263 VOL 8 |
Company News
Bristol-Myers Squibb's Summertime Blues
The sun was shining, savory scents were floating out from the grill, the lemonade was mixed and the table was set. But then dark clouds blew in and settled overhead. Bristol-Myers Squibb's (BMS) picnic got rained out this summer
...Read more
Advertisement
Pharmaceutical companies are effecting a paradigm shift in their focus towards emerging markets driven by the growing economies of these markets and the steady decline of growth opportunities in the developed markets. Varied demography, varied government spending on health and differences in the regulatory environments in individual countries of the emerging markets require global pharmaceutical companies to create and implement specific and custom strategies to succeed in these markets.
The whitepaper examines the current trends, requirements and outsourcing solutions for effective medical communication approach for the emerging markets.  www.sciformix.com/ROI.php |
Drug Development
Public Interest in Private Science: New Ways to Measure R&D Success
Today's big product story — the apparent end to a decade-long drought in the drug development pipeline — is the prep stage for tomorrow's big policy question: are industry R&D priorities in synch with the changing burden of disease?
...Read More
Advertisement
2nd Annual Interactive Response Technologies for Clinical Trials
November 8-9, 2012 * Sonesta Hotel * Philadelphia, PA
Learn best practices in gaining insights into IVR/IWR system utilization in clinical trials and learn how companies are using clinical IRTs to increase efficiencies and decrease costs. Register by November 7, 2012 at  www.cbinet.com/IRT and save $400 with priority code: FHZ888.
|
Regulatory
Forest Labs Hit with Bad Ad Tattle
Forest Labs has had a tough time with regulators over the last two years; the company's sales reps can't seem to stop breaking the law. The latest offense has been brought to light through OPDP's Bad Ad program ...Read More
Advertisement
2nd Global Transparency Reporting Congress—17-18 October, 2012 Amsterdam, Netherlands
Implement Business Processes to Manage and Report HCP Spend Data. Attend the premier Transparency Reporting event of the year and hear best practices for tracking and disclosing data, controlling spend on HCPs, implementing efficient systems and aligning goals across the company from EFPIA, Sanofi, Johnson & Johnson and more! Register by 16 October, 2012 at  www.cbinet.com/transparency and save €300 with priority code: KDZ968.
|
Outsourcing
Strategic Partnerships: The Emperor's New Clothes?
Andrew Parrett argues that strategic partnerships are neither strategic, nor partnerships. And they don't add value to clinical trial outsourcing ...Read more
Advertisement
The Impact of Comparative Effectiveness Research on the Healthcare Community
Live Webcast: Wednesday, August 29, 2012 at 11:00 AM Eastern.
Register Free at  http://www.pharmexec.com/comparative |
Emerging Markets
Six Paths to Emerging Market Success
Ashish Goel and Ramesh Chougule look at six areas where pharma should consider reinventing its supply chain processes and systems to best exploit emerging market opportunities ...Read more |
|
|
 // Merck KGaA made a number of senior US appointments at its EMD Serono division. Evan Lippman (formerly of AstraZeneca) became Senior VP of Neurodegenerative Diseases and Rheumatology. Allene Diaz was appointed to the newly created role of Senior VP, Head of US Oncology. In addition, Rami Levin became VP of Marketing, Neurodegenerative Diseases and Rheumatology, and Craig Millan was appointed Senior VP and Head of EMD Serono's US Fertility, Metabolic Endocrinology and HIV franchise. // Bayer has named current US head of Bayer Healthcare Pharmaceuticals, Philip Blake, as its senior Bayer representative for the US. // Qforma (Santa Fe, NM), a healthcare data analytics and predictive modeling technology provider, announced the appointment of Douglas Thiede to Vice President, Business Development. // Paul Laikind has been named CEO of biotech company ViaCyte, Inc. (San Diego, CA) |
|
|
Advertisement
Meeting Global Patient Demand for Access to Medicines Prior to Approval and Launch
On-Demand Webcast
 http://pharmexec.com/demand |
|
|
|
|
 |
|
 |
|
 |
|
 |
Into which pharmerging market—aside from China and India—is your company most interested in expanding?
|
|
|
|
